Maze Therapeutics, Inc.
NASDAQ:MAZEBiotechnology
+$0.18 today
- Market cap
- $1.71B
- Beta
- 2.26
- P/E (TTM)
- -11.0
- EPS (TTM)
- -$2.27
Volume 0.71M
Average 0.84M
MAZE Other Non-current Liabilities
Long-term obligations not reported separately, such as lease or pension liabilities.
Maze Therapeutics, Inc.NASDAQ: MAZE
Other Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Other non-current liabilities falls 61.4% from a year ago
Other non-current liabilities stood at $388K at the end of Q1 FY2026, down 61.4% from a year earlier and down 64.5% from the prior quarter.
Context
- Other non-current liabilities amounted to 0.1% of total assets at the end of Q1 FY2026, down 0.2 pp from a year earlier.
- Other non-current liabilities increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether other non-current liabilities keeps falling in the next quarterly balance sheet after a -61.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 1.09M USD
- Year-over-year change
- +12.9%
| Period | Period end | Other Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.09M | +12.9% |
| FY2024 | 2024-12-31 | 969K | +96899900.0% |
| FY2023 | 2023-12-31 | 1 | — |
| FY2022 | 2022-12-31 | 0 | — |
Other Non-current Liabilities vs competitors
How MAZE compares with its peers on the latest reported figures
- Peers report in different currencies, so other non-current liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -61.4% is the lowest of 7, against a peer median of +3.6%.
- Other non-current liabilities amounts to 0.1% of total assets for MAZE, versus a peer median of 5.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $2.02B USD | +9.8% | -56.5% | 62.2% | |
| Dec 2025 | €172.9M EUR | +207.0% | +149.7% | 69.5% | |
SEPNSepterna, Inc. | Sep 2026 | $67.13M USD | -44.4% | +12.3% | 10.8% |
| Mar 2026 | $25.86M USD | -2.5% | — | 5.1% | |
| Sep 2026 | $4.89M USD | -17.5% | -53.1% | 0.6% | |
BIOABioAge Labs, Inc. | Mar 2026 | $477K USD | +391.8% | -85.9% | 0.1% |
| Mar 2026 | $388K USD | -61.4% | — | 0.1% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding MAZE) | — | +3.6% | -53.1% | 5.1% | |
Competitors are the stored peer set for MAZE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Maze Therapeutics, Inc.
NASDAQ:MAZE
Intrinsic Alpha fair value
Locked
Current Price
$31.20
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.